NYSEAMERICAN:ATNM - Actinium Pharmaceuticals News Headlines

$0.24
+0.01 (+4.35 %)
(As of 07/19/2019 03:32 PM ET)
Today's Range
$0.23
Now: $0.24
$0.24
50-Day Range N/A
52-Week Range
$0.23
Now: $0.24
$0.87
Volume23,563 shs
Average Volume1.13 million shs
Market Capitalization$38.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) News Headlines

Source:
DateHeadline
How Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Can Impact Your Portfolio VolatilityHow Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Can Impact Your Portfolio Volatility
finance.yahoo.com - July 17 at 4:08 PM
Actinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial CaregiversActinium Highlights Two Presentations at the Health Physics Society Annual Meeting Supporting the Safety Profile of Iomab-B for SIERRA Trial Caregivers
finance.yahoo.com - July 11 at 10:40 AM
Actinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual MeetingActinium Poster Detailing Actinium-225 Labeled Daratumumab Selected in Top Poster Award Competition at 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
finance.yahoo.com - June 27 at 11:18 AM
Actinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual MeetingActinium Presents New Data Demonstrating Effective Lymphodepletion with Lutetium-177 for CAR-T at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
finance.yahoo.com - June 25 at 8:09 AM
Actiniums Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual MeetingActinium's Portfolio of Antibody Radiation-Conjugates to be Highlighted in Two Oral and Two Poster Presentations at the 2019 Society of Nuclear Medicine and Molecular Imaging Annual Meeting
finance.yahoo.com - June 20 at 11:36 AM
Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual MeetingActinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO Annual Meeting
finance.yahoo.com - June 4 at 12:05 PM
Investors Who Bought Actinium Pharmaceuticals (NYSEMKT:ATNM) Shares Five Years Ago Are Now Down 98%Investors Who Bought Actinium Pharmaceuticals (NYSEMKT:ATNM) Shares Five Years Ago Are Now Down 98%
finance.yahoo.com - May 24 at 3:42 PM
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual MeetingAbstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
finance.yahoo.com - May 16 at 9:13 AM
Actinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business OfficerActinium Announces Appointment of Niva Almaula, Ph.D. as Chief Business Officer
finance.yahoo.com - May 7 at 11:52 AM
Mid-Day Market Update: Dow Up Over 100 Points; Actinium Pharmaceuticals Shares PlungeMid-Day Market Update: Dow Up Over 100 Points; Actinium Pharmaceuticals Shares Plunge
www.nasdaq.com - April 18 at 3:54 PM
Actinium prices equity offering; shares down 30% premarketActinium prices equity offering; shares down 30% premarket
seekingalpha.com - April 18 at 12:03 PM
Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and WarrantsActinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants
finance.yahoo.com - April 18 at 12:03 PM
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and WarrantsActinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - April 17 at 4:16 PM
Actiniums Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International SymposiumActinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium
finance.yahoo.com - April 8 at 9:14 AM
Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACRActinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR
finance.yahoo.com - April 3 at 9:34 AM
What Makes Actinium (ATNM) a New Buy StockWhat Makes Actinium (ATNM) a New Buy Stock
finance.yahoo.com - April 1 at 1:18 PM
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 IsotopeActinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope
finance.yahoo.com - March 26 at 11:41 AM
Actinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate HighlightsActinium Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Highlights
finance.yahoo.com - March 20 at 11:35 AM
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory AffairsActinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs
finance.yahoo.com - March 20 at 11:35 AM
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual MeetingActinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting
finance.yahoo.com - March 20 at 11:35 AM
Actinium Pharmaceuticals, Inc. Estimate MomentumActinium Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 18 at 3:48 PM
Actinium Provides Comprehensive Patent Portfolio Update Including New IP FilingsActinium Provides Comprehensive Patent Portfolio Update Including New IP Filings
finance.yahoo.com - March 16 at 12:21 PM
Actinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare ConferenceActinium Pharmaceuticals to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference
finance.yahoo.com - March 15 at 12:12 PM
What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?What Type Of Shareholder Owns Actinium Pharmaceuticals, Inc.’s (NYSEMKT:ATNM)?
finance.yahoo.com - March 7 at 3:49 PM
Actiniums Iomab-B shows positive action in late-stage studyActinium's Iomab-B shows positive action in late-stage study
seekingalpha.com - February 25 at 4:05 PM
Actiniums Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA TrialActinium's Late Breaking Oral Presentation at 2019 TCT Meetings Reports New Data on Donor Chimerism Indicating Deep Engraftment in All Iomab-B Treated Patients in the Pivotal Phase 3 SIERRA Trial
finance.yahoo.com - February 25 at 11:45 AM
Actinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell TherapyActinium Highlights New Data at TCT Meetings Demonstrating Effective Lymphodepletion Supporting Iomab-ACT Program Development for Targeted Conditioning Prior to CAR-T and Adoptive Cell Therapy
finance.yahoo.com - February 21 at 1:17 PM
Consolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes SA, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications - GlobeNewswireConsolidated Research: 2019 Summary Expectations for Caesars Entertainment, Gol Linhas Aereas Inteligentes SA, Zillow Group, Gladstone Land, Actinium Pharmaceuticals, and Kforce — Fundamental Analysis, Key Performance Indications - GlobeNewswire
globenewswire.com - February 15 at 12:08 PM
Iomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual MeetingIomab-B One of Four Late Breaking Oral Presentations to be Presented at the 2019 Transplantation & Cellular Therapy Annual Meeting
finance.yahoo.com - February 12 at 12:06 PM
Actinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion ProgramActinium Provides Patent Portfolio Update for its Iomab-ACT Next-Generation CAR-T Lymphodepletion Program
finance.yahoo.com - February 6 at 11:42 AM
Actinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and VenetoclaxActinium Initiates Novel Phase 1/2 Combination Trial of Actimab-A and Venetoclax
finance.yahoo.com - February 5 at 10:24 AM
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin - PRNewswireActinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin - PRNewswire
www.prnewswire.com - February 4 at 3:48 PM
Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of WisconsinActinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin
finance.yahoo.com - February 4 at 8:20 AM
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7thActinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th
finance.yahoo.com - January 29 at 11:42 AM
Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets 15th Annual Investor ConferenceActinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference
finance.yahoo.com - January 25 at 11:09 AM
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply ChainActinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain
finance.yahoo.com - January 23 at 11:15 AM
Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module InitiatedActinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated
finance.yahoo.com - January 17 at 1:10 PM
Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate TherapiesActinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies
finance.yahoo.com - January 16 at 11:04 AM
Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco - PRNewswireActinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco - PRNewswire
www.prnewswire.com - January 5 at 3:46 PM
Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San FranciscoActinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
finance.yahoo.com - January 3 at 10:50 AM
How Does Investing In Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Impact The Volatility Of Your Portfolio?How Does Investing In Actinium Pharmaceuticals, Inc. (NYSEMKT:ATNM) Impact The Volatility Of Your Portfolio?
finance.yahoo.com - December 21 at 3:52 PM
Actinium Pharmaceuticals Inc (ATNM-US): Hot -2-Actinium Pharmaceuticals Inc (ATNM-US): Hot -2-
www.finanznachrichten.de - December 17 at 10:51 AM
Actinium Pharmaceuticals Inc (ATNM-US): Hot property mis-pricedActinium Pharmaceuticals Inc (ATNM-US): Hot property mis-priced
www.finanznachrichten.de - December 17 at 10:51 AM
Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual MeetingActinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting
finance.yahoo.com - December 4 at 10:39 AM
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate - PRNewswireActinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate - PRNewswire
www.prnewswire.com - December 3 at 3:53 PM
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation ConjugateActinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate
finance.yahoo.com - December 3 at 10:45 AM
Should you buy stock in Aurora Cannabis Inc, Actinium Pharmaceuticals Inc, Canopy Growth Corp, Cronos Group and Helios or Matheson Analytics Inc.?Should you buy stock in Aurora Cannabis Inc, Actinium Pharmaceuticals Inc, Canopy Growth Corp, Cronos Group and Helios or Matheson Analytics Inc.?
www.bizjournals.com - November 30 at 11:17 AM
Actinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare ConferenceActinium Pharmaceuticals, Inc. to Present at 30th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 19 at 10:17 AM
Actinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering ConferenceActinium Pharmaceuticals to Present at BIO-Europe® 24th Annual International Partnering Conference
finance.yahoo.com - November 5 at 8:10 AM
Actinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial DataActinium Pharmaceuticals ASH Annual Meeting Presence to Include Oral Presentation of Feasibility and Safety Results of Iomab-B Pivotal Phase 3 SIERRA Trial and also New Actimab-A Phase 2 Trial Data
finance.yahoo.com - November 1 at 10:00 AM
This page was last updated on 7/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel